ACM
INMB icon

ACT Capital Management’s INmune Bio INMB Stock Holding History

ACT Capital Management’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$937K Sell
151,100
-9,400
-6% -$82.5K 1.29% 18
2022
Q2 		$1.42M Sell
160,500
-70,000
-30% -$521K 1.98% 13
2022
Q1 		$1.94M Hold
230,500
– – 2.05% 13
2021
Q4 		$2.35M Sell
230,500
-44,500
-16% -$659K 1.7% 14
2021
Q3 		$5.34M Buy
+275,000
New +$5.31M 2.77% 8

Other funds holding INMB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

ACT Capital Management's INMB Position: Q3 2022 in Review

ACT Capital Management reduced its INmune Bio (INMB) stake by 5.9% in Q3 2022, selling an estimated $82.5K and leaving 151,100 shares worth $937K. The position accounts for 1.29% of the portfolio, ranked #18.

ACT Capital Management first reported a position in INMB in Q3 2021 and has held it in 5 quarters since. The position peaked at $5.34M in Q3 2021. 33 funds tracked by Wall St. Rank hold INMB as of Q3 2022.

  • ACT Capital Management held 151,100 shares of INmune Bio worth $937K as of Q3 2022.
  • ACT Capital Management sold 9,400 INmune Bio shares in Q3 2022, an estimated $82.5K.
  • INmune Bio made up 1.29% of ACT Capital Management's portfolio in Q3 2022, its #18 holding.
  • ACT Capital Management first reported a position in INmune Bio in Q3 2021 and has held it in 5 quarters since.
  • ACT Capital Management's INmune Bio position peaked at $5.34M in Q3 2021.
  • 33 funds tracked by Wall St. Rank held INmune Bio as of Q3 2022.

Based on ACT Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.